Healthcare can be complicated.
Your cardiology news shouldn’t be.

Join thousands of cardiology leaders today.

Preventive Cardiology March 21, 2024

Questioning Intermittent Fasting’s Cardiovascular Impact March 21, 2024

A new AHA study shocked the world this week, suggesting that intermittent fasting might significantly increase people's risk of cardiovascular death, sparking a wave of media coverage, and frenzy of criticisms from the cardiologist and scientific communities.

Pharmaceuticals March 18, 2024

Silence Therapeutics’ Zerlasiran Shows LP(a) Potential March 18, 2024

Silence Therapeutics’ zerlasiran continued to demonstrate its lipoprotein(a) impact, as topline Phase 2 data showed that the injectable siRNA slashed LP(a) levels by over 90% through 36 weeks.

Obesity Care March 14, 2024

Wegovy Gains Expanded Approval for CVD Risk Reduction March 14, 2024

Wegovy approved for CVD risk reduction, nanopainting anti-blockage drugs, and plenty of other cardiology news.

Preventive Cardiology March 11, 2024

Microplastics, Nanoplastics, and Major Cardiac Events March 11, 2024

A landmark NEJM study revealed that many patients with carotid artery disease might have microplastics and nanoplastics embedded in their carotid plaque, and those patients have a massive 4.5-fold greater risk of heart attack, stroke, or death within three years.

Heart Failure March 7, 2024

Endotronix Cordella Shows HF Impact in PROACTIVE-HF Trial March 7, 2024

Endotronix took a big step toward its vision for pulmonary artery pressure-based heart failure medication optimization, releasing positive results from its Cordella Sensor’s PROACTIVE-HF pivotal trial.

Surgeries & Interventions March 4, 2024

Boston Scientific AGENT Drug-Coated Balloon Lands Long-Awaited FDA Approval March 4, 2024

AGENT DCB lands FDA approval, the benefits of ECG for low-risk patients, and plenty of other cardiology news.

Preventive Cardiology February 29, 2024

Lipoprotein(a)’s High (and Uneven) Cardiovascular Risks February 29, 2024

Harvard researchers strengthened the link between high Lipoprotein(a) levels and greater risks of future cardiovascular events, including among patients who haven’t been diagnosed with ASCVD.

Imaging February 26, 2024

Philips Launches Radiation-Free LumiGuide Navigation System February 26, 2024

Philips made interventional imaging headlines last week, announcing the US and European launch of its LumiGuide interventional imaging system, positioning it as a key step toward “bringing healthcare closer to entirely radiation-free surgery.”

Heart Failure February 22, 2024

Reprieve Cardiovascular Looks to Transform ADHF Decongestion Management February 22, 2024

Reprieve Cardiovascular emerged this week, announcing a hefty $42M Series A round and an even bigger mission to “transform the standard of care” for patients with acute decompensated heart failure.

Surgeries & Interventions February 15, 2024

FDA Panel Strongly Supports Abbott TriClip TEER February 15, 2024

The FDA expert advisory panel votes are in, and they’re pointing in an overwhelmingly positive direction for Abbott's TriClip tricuspid edge-to-edge repair treatment.

Obesity Care February 12, 2024

Gastric Bypass Surgery’s Durable Hypertension Impact February 12, 2024

The associations between obesity and hypertension are widely known, but a new JACC study reveals that weight-reducing gastric bypass surgery has a significant and lasting impact on patients’ need for antihypertensives.

Surgeries & Interventions February 8, 2024

Biosense Webster’s Varipulse PFA Data Impresses at AF Symposium February 8, 2024

Biosense Webster might be a later entry into the AFib pulsed field ablation segment, but new trial data presented at the AF Symposium suggests that the J&J subsidiary’s Varipulse PFA system could make a big impact when it does hit the market.

Surgeries & Interventions February 5, 2024

Edwards EVOQUE First FDA-Approved Transcatheter Tricuspid Regurgitation Treatment February 5, 2024

Edwards Lifesciences ended last week with the biggest structural interventions launch that we’ve seen in some time, announcing the FDA approval of its EVOQUE transcatheter tricuspid valve replacement system.

Surgeries & Interventions February 1, 2024

SAVR’s Value in the TAVR Era February 1, 2024

Procedure trends certainly suggest that we’ve entered the TAVR era, but a pair of new studies show that surgical aortic valve replacement (SAVR) is a far better option for many younger and healthier patients who are increasingly seen as TAVR candidates.

Pharmaceuticals January 29, 2024

Vascepa’s ACS Advantage January 29, 2024

Amarin’s fish oil-based Vascepa (icosapent ethyl, aka IPE) made its mark in 2018’s REDUCE-IT trial after achieving a 25% MACE reduction among high-risk statin users, and new post hoc analysis of the same data suggests that IPE might have an even greater benefit among patients who recently had acute coronary syndrome.

Remote Care January 25, 2024

CardioSignal Looks to Expand CVD Detection through Patients Phones January 25, 2024

Expanding access to heart disease detection is one of cardiology’s biggest challenges, and Finnish startup CardioSignal just raised $10M to address that challenge using one of the most accessible devices in the world - the smartphone.

Cardiovascular Disease January 22, 2024

Lipoprotein(a)’s Outsized Per-Particle Risks January 22, 2024

A pair of JACC studies layed what might be a new scientific foundation for all that research showing that people with high lipoprotein(a) have elevated cardiovascular risks.

Cardiology Practices January 18, 2024

Private Equity’s Cardiovascular Expansion January 18, 2024

Private equity’s massive expansion across US healthcare has largely skipped cardiology, but a new JAMA paper suggests that cardiovascular clinicians should expect PE to have a much greater influence within their specialty going forward.

Cardiology Pharmaceuticals January 11, 2024

Strong-HF Analysis Supports Quick HF Medication Optimization January 11, 2024

Secondary analysis of Strong-HF trial data highlighted the benefits of quickly bringing heart failure patients up to full guideline-directed medical therapy (GDMT), showing that rapid uptitration to optimal doses reduces readmissions and mortality, while improving quality of life.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!